PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients
Author(s):
Graaf, W.T.A. van der; Blay, J.Y.; Chawla, S.P.; Kim, D.W.; Nguyen, B.B.; Casali, P.G.; Schoffski, P.; Aglietta, M.; Staddon, A.P.; Beppu, Y.; Cesne, A. le; Gelderblom, H.; Judson, I.R.; Araki, N.; Ouali, M.; Marreaud, S.; Hodge, R.; Dewji, M.; Tos, A.P. dei; Hohenberger, P.
